Acurx Pharmaceuticals (ACXP) Projected to Post Earnings on Wednesday

Acurx Pharmaceuticals (NASDAQ:ACXP) is expected to be announcing its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($1.61) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 8:00 AM ET.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its earnings results on Monday, August 11th. The company reported ($1.89) earnings per share for the quarter, topping the consensus estimate of ($2.00) by $0.11. On average, analysts expect Acurx Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acurx Pharmaceuticals Trading Down 5.4%

Shares of Acurx Pharmaceuticals stock opened at $4.73 on Monday. The business’s fifty day moving average price is $5.20 and its 200 day moving average price is $6.88. Acurx Pharmaceuticals has a twelve month low of $3.80 and a twelve month high of $38.00. The stock has a market capitalization of $7.47 million, a P/E ratio of -0.44 and a beta of -1.27.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ACXP shares. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 price objective on shares of Acurx Pharmaceuticals in a research note on Tuesday, September 30th. Wall Street Zen lowered shares of Acurx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, October 19th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Acurx Pharmaceuticals presently has an average rating of “Hold” and an average price target of $31.00.

Institutional Investors Weigh In On Acurx Pharmaceuticals

A hedge fund recently bought a new stake in Acurx Pharmaceuticals stock. Armistice Capital LLC acquired a new stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,078,540 shares of the company’s stock, valued at approximately $551,000. Armistice Capital LLC owned about 70.13% of Acurx Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 11.53% of the company’s stock.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.